Data Sheet (Cat.No.T1029)



Aztreonam

Chemical Properties

CAS No.: 78110-38-0

Formula: C13H17N5O8S2

Molecular Weight: 435.43

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

| Description | Aztreonam (SQ-26,776), a monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum, possesses bactericidal activity. | | | | |
|---------------|---|--|--|--|--|
| Targets(IC50) | Antibacterial,Antibiotic | | | | |
| In vitro | Aztreonam causes significant suppression of human colony forming unit-erythroid (cfue), burst forming unit-erythroid (bfu-e) and colony forming unit-granulocyte macrophage (cfu-gm) at both peak and trough serum concentrations in human bone marrow cells. [1] Aztreonam is hydrolyzed at measurable rates by class A betalactamases, a TEM-2 type penicillinase and the Proteus vulgaris cephalosporinase with a broad substraterange. Aztreonam is extremely stable as to the typical class C cephalosporinase of Citrobacter freundii, and acts as a competitive and progressive inhibitor for the beta-lactamase. [2] Aztreonam (AZT) combined with clindamycin (CLDM) has synergistic effects on Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, and Haemophilus influenzae, which are sensitive or quasisensitive to CLDM, in the presence of CLDM at MIC or sub-MIC. [3] Aztreonam reduces the cfu of some strains by 1 log unit without preserving the integrity of cystic fibrosis airway cell monolayers, while decreasing the biofilms of other clinical isolates by 4 log units and protecting the monolayers from being compromised. [4] | | | | |
| In vivo | Aztreonam (300 mg/kg) results in a significant decrease in the content of hepatic microsomal P450, while no significant change is observed in hepatic cytochrome b5 content and NADPH-cytochrome c (P450) reductase activity. | | | | |

Solubility Information

| Solubility | H2O: 9 mg/mL (20.67 mM), Sonication is recommended. | | |
|------------|---|--|--|
| | DMSO: 50 mg/mL (114.83 mM), Sonication is recommended. | | |
| | Ethanol: < 1 mg/mL (insoluble or slightly soluble), | | |
| | (< 1 mg/ml refers to the product slightly soluble or insoluble) | | |

Page 1 of 2 www.targetmol.com

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|-----------|------------|------------|
| 1 mM | 2.2966 mL | 11.4829 mL | 22.9658 mL |
| 5 mM | 0.4593 mL | 2.2966 mL | 4.5932 mL |
| 10 mM | 0.2297 mL | 1.1483 mL | 2.2966 mL |
| 50 mM | 0.0459 mL | 0.2297 mL | 0.4593 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Charak BS, et al. J Antimicrob Chemother, 1991, 27(1), 95-104.

Sakurai Y, et al. J Antibiot (Tokyo), 1990, 43(4), 403-410.

Deguchi K, et al. Jpn J Antibiot, 1991, 44(5), 529-537.

Yu Q, et al. J Antimicrob Chemother, 2012, 67(11), 2673-2681.

Ohmori S, et al. Pharmacology, 1994, 48(3), 137-142.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481

Page 2 of 2 www.targetmol.com